1. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction of DPYD and fluoropyrimidines
- Author
-
Lunenburg, C.A.T.C. (Carin A. T. C.), van der Wouden, C.H. (Cathelijne H.), Nijenhuis, M. (M.), Crommentuijn-van Rhenen, M.H. (Mandy H.), de Boer-Veger, N.J. (Nienke J.), Buunk, A.M. (Anne Marie), Houwink, E.J.F. (Elisa J. F.), Mulder, H. (Hans), Rongen, G.A. (Gerard), Schaik, R.H.N. (Ron) van, Weide, J. (Jan) van der, Wilffert, B. (Bob), Deneer, V.H.M. (V. H M), Swen, J.J. (Jesse), Guchelaar, H.J. (Henk Jan), Lunenburg, C.A.T.C. (Carin A. T. C.), van der Wouden, C.H. (Cathelijne H.), Nijenhuis, M. (M.), Crommentuijn-van Rhenen, M.H. (Mandy H.), de Boer-Veger, N.J. (Nienke J.), Buunk, A.M. (Anne Marie), Houwink, E.J.F. (Elisa J. F.), Mulder, H. (Hans), Rongen, G.A. (Gerard), Schaik, R.H.N. (Ron) van, Weide, J. (Jan) van der, Wilffert, B. (Bob), Deneer, V.H.M. (V. H M), Swen, J.J. (Jesse), and Guchelaar, H.J. (Henk Jan)
- Abstract
Despite advances in the field of pharmacogenetics (PGx), clinical acceptance has remained limited. The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate PGx implementation by developing evidence-based pharmacogenetics guidelines to optimize pharmacotherapy. This guideline describes the starting dose optimization of three anti-cancer drugs (fluoropyrimidines: 5-fluorouracil, capecitabine and tegafur) to decrease the risk of severe, potentially fatal, toxicity (such as diarrhoea, hand-foot syndrome, mucositis or myelosuppression). Dihydropyrimidine dehydrogenase (DPD, encoded by the DPYD gene) enzyme deficiency increases risk of fluoropyrimidine-induced toxicity. The DPYD-gene activity score, determined by four DPYD variants, predicts DPD activity and can be used to optimize an individual’s starting dose. The gene activity score ranges from 0 (no DPD activity) to 2 (normal DPD activity). In case it is not possible to calculate the gene activity score based on DPYD genotype, we recommend to determine the DPD activity and adjust the initial dose based on available data. For patients initiating 5-fluorouracil or capecitabine: subjects with a gene activity score of 0 are recommended to avoid systemic and cutaneous 5-fluorouracil or capecitabine; subjects with a gene activity score of 1 or 1.5 are recommended to initiate therapy
- Published
- 2019
- Full Text
- View/download PDF